Harmony Biosciences reported third‑quarter 2025 revenue of $239.5 million, a 29% year‑over‑year increase driven by its flagship drug WAKIX. The company’s GAAP net income for the quarter was $50.9 million, while non‑GAAP adjusted net income reached $63.5 million.
GAAP earnings per share for Q3 2025 were $0.87, and non‑GAAP adjusted EPS was $1.08. The company beat consensus revenue estimates of $228.95 million and EPS estimates of $0.92.
The quarter also saw the largest increase in the average number of patients on WAKIX, rising by roughly 500 to an average of 8,100 patients. Prior‑period comparisons show Q3 2024 revenue of $186 million, GAAP EPS of $0.79, and non‑GAAP EPS of $0.99; Q2 2025 revenue was $200.5 million with GAAP EPS of $0.68 and non‑GAAP EPS of $0.92.
Harmony raised its full‑year 2025 revenue guidance to $845 million–$865 million, reflecting continued momentum. The company’s cash position stood at $778 million at the end of Q3 2025, supporting a pipeline that includes up to five Phase 3 programs, including Pitolisant HD and ZYN002.
WAKIX remains the first FDA‑approved H3 receptor antagonist/inverse agonist for narcolepsy, and Harmony holds an exclusive U.S. license for the drug. The company’s strategic focus is on maintaining profitability while advancing its neuroscience pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.